State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA)

State Street Corp grew its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 47.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 395,059 shares of the company’s stock after buying an additional 127,300 shares during the quarter. State Street Corp owned 0.59% of Zura Bio worth $1,604,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Braidwell LP bought a new stake in shares of Zura Bio in the third quarter worth $10,040,000. MetLife Investment Management LLC purchased a new stake in shares of Zura Bio during the 3rd quarter valued at about $111,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Zura Bio in the third quarter worth approximately $46,000. The Manufacturers Life Insurance Company purchased a new position in shares of Zura Bio during the 3rd quarter worth $71,000. Finally, Valence8 US LP purchased a new position in Zura Bio during the third quarter valued at $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ZURA. Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Stock Performance

ZURA opened at $2.50 on Thursday. The company has a 50-day moving average price of $3.24 and a 200 day moving average price of $3.61. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). As a group, equities analysts forecast that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.